The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

Journal of Gene Medicine

Volumn 5, Issue 4, 2003, Pages 300-310

  Barker, Shannon D ^a,b,e   Coolidge, Candace J ^c   Kanerva, Anna ^a,b   Hakkarainen, Tanja ^f   Yamamoto, Masato ^a,b   Liu, Bin ^a,b   Rivera, Angel A ^a,b   Bhoola, Snehal M ^b,d   Barnes, Mack N ^b,d   Alvarez, Ronald D ^b,d   Curiel, David T ^a,b,e   Hemminki, Akseli ^a,b,e,g,h  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e and Radiation Oncology   (United States)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h NONE   (Finland)

Author keywords

Adenovirus; Gene therapy; Ovarian cancer; Secretory leukoprotease inhibitor; Tissue specific promoters

Indexed keywords

ADENOVIRUS VECTOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; CYCLOOXYGENASE 2; ISOENZYME; LEUKOCYTE ELASTASE INHIBITOR; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROTEIN; PTGS2 PROTEIN, HUMAN; SLPI PROTEIN, HUMAN; SLPI PROTEIN, MOUSE; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE; TRANSGENE; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; ADENOCARCINOMA; ANIMAL; CELL CULTURE; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; LIVER; METABOLISM; METASTASIS; METHODOLOGY; MOUSE MUTANT; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHYSIOLOGY;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; ISOENZYMES; LIVER; MEMBRANE PROTEINS; MICE; MICE, SCID; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0642275637     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.341     Document Type: Article

References (51)

1. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 1994; 716: 90-101.
2. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997; 40: 137-206.
3. Rosenfeld M, Wang M, Siegal G, et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996; 74: 455-462.
4. Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? BioDrugs 2002; 16: 77-87.
5. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an EIB-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trail. Gene Ther 2001; 8: 308-315.
6. Stewart A, Lassam N, Quirt I, et al. Adenovector-mediated gene delivery to interleukin-2 in metastatic breast cancer and melanoma: results of a phase I clinical trail. Gene Ther 1999; 6: 350-363.
7. Sung M, Yeh H, Thung S, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma:results of a phase I clinical trial. Mol Ther 2001; 4: 182-191.
8. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 2: 524-530.
9. Tomko RP, Xu R, Philipson L. The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackie viruses. Proc Natl Acad Sci U S A 1997; 94: 3352-3356.
10. Yang Y. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
11. Yang Y. Immune responses to vital antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-144.
12. Vassaux G, Hurst HC, Lemoine NR. Insulation of a tumour-selective conditional expression cassette in an adenoviral vector. Gene Ther 1999; 6: 1192-1197.
13. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997; 8: 803-815.
14. Chung I, Schwartz P, Crystal R, et al. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther 1999; 6: 99-106.
15. Peng X, Won J, Rutherford T, et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression of ovarian and bladder cancer cell lines. Cancer Res 2001; 61: 4405-4413.
16. Yamamoto M, Alemany R, Adachi Y, et al. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001; 3: 385-394.
17. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgene in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-2504.
18. Garver R, Goldsmith K, Rodu B, et al. Strategy for achieving selective killing of carcinomas. Gene Ther 1994; 1: 46-50.
19. Robertson M, Wang M, Siegal G, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther 1998; 5: 331-336.
20. Abe T, Tominaga Y, Kikuchi T, et al. Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung. Am J Respir Crit Care Med 1997; 156: 1235-1240.
21. Hough C, Sherman-Baust C, Pizer E, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000; 60: 6281-6287.
22. Hough C, Cho K, Zonderman A, et al. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001; 61: 3869-3876.
23. Kanerva A, Wang M, Bauerschmitz G, et al. Gene transfer to ovarian cancer versus normal tissues with fiber modified adenoviruses. Mol Ther 2002; 5: 695-704.
24. Raper S, Yudkoff M, Chirmule N, et al. A pilot study on in vivo directed gene transfer with an adenoviral vector in partial orthinine transcarbamylase deficiency. Hum Gene Ther 2002; 13 163.
25. Barker S, Casado E, Gomez-Navarro J, et al. An immuno-magnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57-63.
26. Kanerva A, Mikheeva G, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280.
27. He T, Zhou S, da Costa L, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci 1998; 95: 2509-2514.
28. Rancourt C, Rogers B, Sosnowski B, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 1-7.
29. Inoue H, Nanayama R, Hara S, et al. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett 1994; 350: 51-54.
30. Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995; 270: 24965-24971.
31. Hemminki A, Belousova N, Zinn K, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001; 4: 223-231.
32. Sandmair A, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2001; 11: 2197-2205.
33. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
34. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fiuorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
35. Marshall E. Clinical trials: gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
36. Ring C, Harris JD, Hurst HC, et al. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-1103.
37. Shi Q, Wang Y, Worton D. Modulation of the specificity and activity of a cellular promoter in an adenoviral context. Hum Gene Ther 1997; 8: 403-410.
38. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991; 87: 2207-2215.
39. Tait DL, Obermiller P, Hatmaker A, et al. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999; 5: 1708-1714.
40. Hasenburg A, Tong X, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecam chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839-852.
41. Mahasreshti P, Gomez-Navarro J, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001; 7: 2057-2066.
42. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotech 2000; 18: 723-727.
43. Yu D, Chen Y, Seng M, et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-4203.
44. Yu D, Sakamoto G, Henderson D. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication-competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-1504.
45. Rodriguez R, Schuur E, Lim H, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
46. Kurihara T, Brough D, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
47. Hallenbeck P, CHang Y, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-1733.
48. Adachi Y, Reynolds P, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
49. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther 1996; 3: 1094-1103.
50. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther 1997; 8: 403-410.
51. Steinwaerder DS, Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 2000; 7: 56-567.